Lymphoma Risk following Guselkumab, Risankizumab, or Tildrakizumab Use: A Descriptive Analysis

Basic Details
Date Posted
Tuesday, March 30, 2021
Status
Complete
Medical Product
guselkumab
risankizumab
tildrakizumab
Health Outcome(s)
lymphoma
Description

In this report we examined total available follow-up time of patients exposed to guselkumab, risankizumab, or tildrakizumab in the Sentinel Distributed Database (SDD). This is the first report of an ongoing plan to monitor uptake of these drugs until sufficient follow-up time accrues among treated patients to conduct a 1:1 propensity-score-matched analysis for non-Hodgkin lymphoma (NHL) in this cohort. We distributed this request to 16 Sentinel Data Partners on July 6, 2020. The study period included data from July 13, 2017 through December 31, 2019.

Additional Details
FDA Center
CDER
Time Period
July 13, 2017 - December 31, 2019
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Individuals 18 years of age and older
Data Sources
Sentinel Distributed Database (SDD)